Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference
Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. EST. CEO Richard Pops will lead the presentation, followed by a Q&A session. The event will be accessible via live webcast on the company's investor relations page and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a portfolio aimed at addiction, schizophrenia, and bipolar I disorder.
Positive
- Scheduled corporate update at a prestigious healthcare conference.
- Focus on innovative medicines in high-demand therapeutic areas.
Negative
- None.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was +3.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 12, 2022 at 11:15 a.m. EST (4:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-40th-annual-jp-morgan-healthcare-conference-301454212.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.